Brazil Approves Earlier Use of HER2-Positive Breast Cancer Therapy
Brazil's National Health Surveillance Agency (Anvisa) has approved a new indication for Enhertu (trastuzumab deruxtecan), a medication previously used for certain breast cancer types. This expanded approval allows the therapy to be administered earlier in treatment for adults with early-stage HER2-positive breast cancer who still show signs of the disease after chemotherapy, targeted therapy, and surgery. Specifically, it applies to patients with invasive residual disease, meaning cancer cells remain in tissue removed during surgery despite prior treatment aimed at reducing or eliminating the tumor. This patient group faces a higher risk of disease recurrence, with up to 25% potentially experiencing a relapse within 10 years. Oncologist Stephen Stefani highlighted that while the drug was already used for advanced HER2-positive tumors, its new indication targets an earlier disease phase with the goal of increasing cure rates. The approval stems from a clinical study demonstrating a 53% reduction in the risk of invasive recurrence or death, alongside improved disease-free survival. Enhertu is an antibody-drug conjugate that targets the HER2 protein on cancer cells, delivering a cytotoxic agent to kill them. It combines targeted therapy with chemotherapy and possesses a "bystander effect" that can affect nearby cancer cells. Despite Anvisa's approval, Enhertu is not yet available through Brazil's public health system (SUS), pending an incorporation evaluation that considers clinical benefit, safety, cost, and health system impact. The HER2-positive subtype accounts for 10-19% of breast cancer cases, historically associated with poorer prognoses, but advancements in targeted therapies have improved outcomes.
Anvisa's early approval of Enhertu for residual HER2-positive breast cancer signifies a strategic shift towards more aggressive, earlier intervention in oncology. This move reflects a growing understanding of disease dynamics, where targeting residual microscopic disease post-surgery can significantly impact long-term survival. The technology's sophisticated delivery mechanism, combining targeted therapy with a chemotherapy payload and a bystander effect, represents an evolution in precision medicine, aiming to maximize tumor eradication while minimizing collateral damage to healthy cells. However, the subsequent integration into public healthcare systems like Brazil's SUS presents a critical challenge. Balancing the clinical imperative for advanced therapies with economic realities and system capacity will be a recurring theme in the coming decade. Policymakers face the complex task of ensuring equitable access to life-saving innovations without compromising the financial sustainability of public health infrastructure, a tension that will likely intensify as novel treatments proliferate.
AI-generated to prompt reflection — not editorial opinion, not advice, not a statement of fact. How this works.